Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
Checked against the public recordLast updated Jul 10, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Revolution Medicines, Inc.
- Interventions being studied
- Drug: RMC-5127; Drug: daraxonrasib; Drug: cetuximab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy. * Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage. * Measurable per RECIST v1.1 * Adequate organ function (bone marrow, liver, kidney, coagulation). * Able to take oral medications. Exclusion Criteria: * Primary central nervous system (CNS) tumors * Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy (eg. degraders and/or inhibitors). * Any conditions that may affect the ability to take or absorb study drug. * Major surgery within 28 days prior to receiving study drug(s). * Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Yale Cancer CenterNew Haven, Connecticut
- Johns HopkinsBaltimore, Maryland
- Dana-Farber Cancer InstituteBoston, Massachusetts
- START MidwestGrand Rapids, Michigan
- Laura and Isaac Perlmutter Cancer Center at NYU Langone HealthNew York, New York
- NEXT - DallasDallas, Texas
- NEXTSan Antonio, Texas
- START - San AntonioSan Antonio, Texas
- NEXT - VirginiaFairfax, Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 10, 2026. Always confirm current availability with the study team.